Biovica will present at ABGs Introduce Investor Day, a small-cap investor seminar, held on December 4 at Haymarket in Stockholm. The company will be represented by CEO Anders Rylander in Track 2 at 10.30 CET.

For full program and registration, see link:—v3/. The event will also be livestreamed at


More information:

Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.

Read more: